Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Designed drug trial seeks to shrink tough cancers

NCT ID NCT05985655

Recruiting now Disease control Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called GTAEXS617 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like head & neck, lung, pancreatic, ovarian, and breast cancer. It is an early-phase trial for 230 participants to gather initial safety and effectiveness data.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Sart Tilman

    RECRUITING

    Liège, Belgium

    Contact

  • Clinique Universitaires Saint-Luc

    RECRUITING

    Brussels, Belgium

    Contact

  • GZA Ziekenhuizen - Campus Sint-Augustinus

    RECRUITING

    Antwerp, Belgium

  • Institute Jules Bordet

    RECRUITING

    Brussels, Belgium

  • Newcastle Upon Tyne NHS Foundation Trust

    RECRUITING

    Newcastle upon Tyne, United Kingdom

    Contact

  • Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, United Kingdom

    Contact

  • START Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • START Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

  • START San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • The Beatson West of Scotland Cancer Centre

    RECRUITING

    Glasgow, United Kingdom

    Contact

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, United Kingdom

    Contact

  • UCL Hospitals NHS Foundation Trust

    RECRUITING

    London, United Kingdom

    Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR BREAST CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS (HGSOC) HORMONE RECEPTOR POSITIVE [HR+] AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE [HER2-] BREAST CARCINOMA NON-SMALL CELL LUNG CANCER (NSCLC) PANCREATIC ADENOCARCINOMA PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS (HGSOC) TRIPLE NEGATIVE BREAST CANCER (TNBC)